GlassScriptPhysician profile
Anna C Fowler
NPI 1942924881
$5,430.49
in general payments reported to CMS, 2019-2025
26 companies · $2,035 in 2025
The $2,035 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $77.02 · 2023: $1,576 · 2024: $1,742 · 2025: $2,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,312 · Education: $41.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,311.50 |
| Education | $41.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,047.18 | 2022-2025 | |
| Janssen Biotech, INC. | $699.56 | 2023-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $679.09 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $491.07 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $323.48 | 2022-2025 | Xifaxan, Trulance |
| Madrigal Pharmaceuticals | $244.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $224.89 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $223.23 | 2023-2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $184.85 | 2024-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $166.46 | 2022-2025 | Givlaari |
| Genzyme Corporation | $146.63 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $131.63 | 2023-2025 | Rebyota, Cimzia |
| Ironwood Pharmaceuticals, INC | $127.20 | 2023-2025 | Linzess |
| Phathom Pharmaceuticals, INC. | $125.22 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $116.59 | 2023-2025 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $113.98 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $83.13 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $68.08 | 2023 | |
| Ardelyx, INC. | $62.21 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $41.97 | 2023-2024 | Zymfentra, Yuflyma |
| Vivus LLC | $39.04 | 2025 | Pancreaze |
| Shield Therapeutics INC | $22.10 | 2025 | |
| Fresenius Kabi USA, LLC | $20.54 | 2023 | Idacio |
| Celgene Corporation | $18.92 | 2024 | Zeposia |
| Evoke Pharma, INC. | $16.47 | 2025 | |
| Organon LLC | $12.26 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.